

# Interethnic Difference in the Allelic Distribution of Human Epidermal Growth Factor Receptor Intron 1 Polymorphism<sup>1</sup>

Wanqing Liu, Federico Innocenti, Peixian Chen, Soma Das, Edwin H. Cook, Jr., and Mark J. Ratain<sup>2</sup>

Departments of Medicine [W. L., F. I., M. J. R.], Human Genetics [P. C., S. D., E. H. C.], and Psychiatry and Pediatrics [E. H. C.], Committee on Clinical Pharmacology and Pharmacogenomics [F. I., E. H. C., M. J. R.], and Cancer Research Center [F. I., M. J. R.], The University of Chicago, Chicago, Illinois 60637

## ABSTRACT

**Purpose:** Epidermal growth factor receptor (EGFR) plays a critical role in signal transduction and is a target for a novel class of anticancer agents that aim to inhibit EGFR-mediated cancer cell growth. Previous studies have demonstrated a dinucleotide (CA)<sub>n</sub> repeat polymorphism in intron 1 of *EGFR*, ranging from 14 to 21 repeats, that has been suggested to regulate *EGFR* expression. The longer allele with 21 repeats showed an 80% reduction of gene expression compared with the shorter allele with 16 repeats. Therefore, the evaluation of the allelic distribution of this polymorphism in populations of various ethnic origins will be crucial to understand the interindividual variability in *EGFR* expression.

**Experiment Design:** We evaluated the influence of ethnicity on this polymorphism by genotyping individuals of Caucasian ( $n = 183$ ), African-American ( $n = 84$ ), and Asian ( $n = 66$ ) background.

**Results:** The frequency of one of the longer alleles, allele 20 is significantly higher in Asian individuals (63% compared with 21% in Caucasians,  $P = 2 \times 10^{-18}$ ). In confirmation of prior studies, the shorter allele 16 was the most common allele in Caucasians (43%) and African-Americans (42%), but its frequency was significantly lower in Asians (average 17%,  $P = 10^{-7}$  compared with Caucasians).

**Conclusion:** Major interethnic differences in the allelic frequencies of the *EGFR* intron 1 polymorphism exist. Our

results may contribute to a better understanding of the molecular basis underlying ethnic differences in drug response and may be helpful for future strategies of individualized therapy with EGFR inhibitors.

## INTRODUCTION

Human *EGFR* gene is located on chromosome 7p12.1–12.3. Its product, a  $M_r$  170,000 transmembrane glycoprotein, plays a critical role in the signal transduction pathway for cell proliferation, differentiation, and survival. Overexpression of *EGFR* is found in ~30% of human primary tumors (reviewed in Ref. 1) and has been significantly associated with disease stage, prognosis, survival, and response to chemotherapy (2–11). Therefore, *EGFR*<sup>3</sup> is an attractive target for treatment and prevention of cancer. Recent studies have demonstrated encouraging results with three EGFR-targeting inhibitors: cetuximab (IMC-225), a monoclonal antibody with affinity to the extracellular domain of EGFR, and two small EGFR-specific tyrosine kinase inhibitors, gefitinib (ZD1839) and erlotinib (OSI-774; Refs. 1, 12–16). Preliminary results in patients receiving gefitinib showed the presence of interethnic differences in drug response, with Japanese patients having a higher response rate than Caucasians (17).

A highly polymorphic (CA)<sub>n</sub> repeat was identified in intron 1 of the *EGFR* gene, and allelic frequencies in Caucasians were reported (18). Eight alleles from repeat numbers 14–21 were found. Allele 16 (alleles named according to the number of repeats) showed the highest frequency (42%), followed by allele 20 (26%), 18 (20%), and 21 (5%). Other alleles were relatively rare (18).

Recent *in vitro* and *in vivo* studies demonstrated that *EGFR* gene transcription activity declines with increasing number of CA repeats. The longer allele 21 showed 80% reduction of gene expression compared with the shorter allele 16 (19). In another study on breast cancer tissue, a similar effect of this (CA)<sub>n</sub> polymorphism was reported (20).

Because of the fact that limited data are available on the frequency distribution of this polymorphism in populations of different ethnicity, here we report the allelic distribution of the (CA)<sub>n</sub> polymorphism in Caucasian, African-American, and Asian populations.

## MATERIALS AND METHODS

**Samples.** A total of 333 samples were analyzed, including 183 Caucasian, 84 African-American, and 66 Asian sam-

Received 8/23/02; revised 11/13/02; accepted 11/19/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This Pharmacogenetics of Anticancer Agents Research Group study was supported by grant GM61393 from the NIH. The primary data will be deposited into PharmGKB ([www.pharmgkb.org](http://www.pharmgkb.org)), supported by a grant from the NIH (GM61374). This study was also supported by the O'Connor Foundation.

<sup>2</sup> To whom requests for reprints should be addressed, at The University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637. Phone: (773) 702-4400; Fax: (773) 702-3969; E-mail: [mratain@medicine.bsd.uchicago.edu](mailto:mratain@medicine.bsd.uchicago.edu).

<sup>3</sup> The abbreviation used is: EGFR, epidermal growth factor receptor.

Table 1 Allelic distribution of EGFR intron 1 (CA)<sub>n</sub> polymorphism in Caucasian, African-American, and Asian populations

| Allele                                             | Caucasians |                   | African-Americans |      | Chinese     |                  | Non-Chinese Asians |      | Total Asians |                   |
|----------------------------------------------------|------------|-------------------|-------------------|------|-------------|------------------|--------------------|------|--------------|-------------------|
|                                                    | No.        | Freq <sup>a</sup> | No.               | Freq | No.         | Freq             | No.                | Freq | No.          | Freq              |
| 9                                                  | 0          | 0.0               | 0                 | 0.0  | 1           | 1.9              | 0                  | 0.0  | 1            | 0.8               |
| 14                                                 | 1          | 0.3               | 2                 | 1.2  | 0           | 0.0              | 1                  | 1.3  | 1            | 0.8               |
| 15                                                 | 13         | 3.6               | 7                 | 4.2  | 2           | 3.8              | 2                  | 2.5  | 4            | 3.0               |
| 16                                                 | 158        | 43.2              | 70                | 41.7 | 3           | 5.8 <sup>b</sup> | 20                 | 25.0 | 23           | 17.4 <sup>c</sup> |
| 17                                                 | 21         | 5.7               | 26                | 15.5 | 3           | 5.8              | 1                  | 1.3  | 4            | 3.0               |
| 18                                                 | 59         | 16.1              | 11                | 6.5  | 1           | 1.9              | 0                  | 0.0  | 1            | 0.8               |
| 19                                                 | 7          | 1.9               | 15                | 8.9  | 4           | 7.7              | 4                  | 5.0  | 8            | 6.1               |
| 20                                                 | 77         | 21.0              | 24                | 14.3 | 34          | 65.4             | 49                 | 61.3 | 83           | 62.9 <sup>d</sup> |
| 21                                                 | 27         | 7.4               | 13                | 7.7  | 3           | 5.8              | 3                  | 3.8  | 6            | 4.5               |
| 22                                                 | 3          | 0.8               | 0                 | 0.0  | 1           | 1.9              | 0                  | 0.0  | 1            | 0.8               |
| Number of chromosomes                              | 366        |                   | 168               |      | 52          |                  | 80                 |      | 132          |                   |
| 95% confidence interval for frequency of allele 16 | 0.38–0.48  |                   | 0.34–0.49         |      | 0.0079–0.12 |                  | 0.15–0.35          |      | 0.11–0.24    |                   |

<sup>a</sup> Freq. refers to allelic frequency and is expressed as percentage.

<sup>b</sup> Allele 20,  $p = 0.0045$  compare to Non-Chinese Asian populations, Fisher's Exact test, two-tailed.

<sup>c</sup> Allele 16,  $\chi^2 = 27.8$ , degrees of freedom = 1,  $P = 10^{-7}$  compared with Caucasians.

<sup>d</sup> Allele 20,  $\chi^2 = 76.8$ , degrees of freedom = 1,  $P = 2 \times 10^{-18}$  compared with Caucasians.

ples. The Asian group comprised 26 Chinese, 10 Japanese, 20 Native Taiwanese, and 10 Southeast Asian individuals. DNA samples of Caucasian and African-American individuals were obtained from Dr. Funmi Olopade (Department of Medicine, University of Chicago), the Coriell Cell Repositories (Camden, NJ) and the Liver Core Bank Facility (a gift of Dr. Mary Relling, St. Jude Children's Research Hospital, Memphis, TN) of the Pharmacogenetics of Anticancer Agents Research Group. Sixteen Chinese samples were obtained from Dr. Anna Di Rienzo (Department of Human Genetics, University of Chicago), and 50 Asian DNA samples were obtained from the Coriell Cell Repositories.

**Genotyping and Data Analysis.** PCR was performed to amplify the target sequence. Primers were designed as described previously (18). One primer was labeled with fluorescein at the 5' end. The genotyping procedure was performed according to a protocol reported previously (21). Fragment length was determined by direct sequencing. Capillary electrophoresis for sequencing and genotyping was performed on an ABI 3700 DNA sequencer in the DNA sequencing and genotyping core of the University of Chicago Cancer Research Center. Significance was performed either by Fisher's exact or  $\chi^2$  tests with  $P < 0.05$  regarded as the cutoff for statistical significance.

## RESULTS

In 666 chromosomes, 9 alleles with 14–22 CA repeats and 2 rare alleles with 9 and 23 repeats were found (Table 1). The allele frequencies in Caucasians were in agreement with previous data (18). However, the frequency of allele 20 was much higher in Asian individuals (varying from 45 to 80% in different Asian groups, average 63%) compared with 21% in Caucasians ( $\chi^2 = 76.8$ ;  $P = 2 \times 10^{-18}$ ). Allele 20 had a lower frequency in African-Americans (14%) compared with Caucasians, al-




Fig. 1 Frequency of 16 of 16, 16 of 20, and 20 of 20 genotypes in Caucasian, African-American, and Asian populations.

though statistical significance is not reached ( $P = 0.06$ ) probably because of different sample sizes. Allele 16 was the most common allele in Caucasians (43%) and African-Americans (42%), but its frequency was significantly lower in Asians (varying from 6 to 35% in different Asian groups, average 17%;  $\chi^2 = 27.8$ ;  $P = 10^{-7}$  compared with Caucasians). Concerning genotype frequencies, a genotype of 20/20 was the most common genotype in Asians with significantly higher frequency (average 41%) compared with Caucasians (7%;  $\chi^2 = 41.11$ ;  $P = 1.44 \times 10^{-10}$ ) or African-Americans (1%), whereas 16/16 was the most common genotype in both Caucasians (18%) and African-Americans (15%) but not in Asians (average 5%; Fig. 1). In Asian populations, allele 16 showed much lower frequency in Chinese (6%), compared with non-Chinese Asians (25%;  $P = 0.0045$ , Fisher's Exact test, two-tailed).

Hardy-Weinberg equilibrium was tested in each ethnic group, and no significant deviation was found (data not shown).

## DISCUSSION

Interethnic differences in the distribution of genetic polymorphisms in drug metabolizing enzymes, targets, receptors, and transporters are very common (22). For example, the variants in the *thiopurine methyltransferase* gene showed significant interethnic difference in global populations (22); similar findings were observed for a common length polymorphism in the thymidylate synthase 5' untranslated region (23, 24). The population differences in the allelic distribution of *EGFR* intron 1 (CA)<sub>n</sub> polymorphism may be attributable to either the natural selection of an advantageous allele by unknown environmental factors or the fixation of allele frequency through a founder effect. Data from many genome-wide polymorphisms in Chinese compared with Caucasians and other populations indicated the contributions of a founder effect and population expansion to allelic population structure (22–25).

This population disparity is also an important factor that may contribute to interindividual variation in drug response and toxicity (22). Given the association between gene expression and the polymorphic (CA)<sub>n</sub> repeat, our study suggests that the response to anticancer therapies with EGFR inhibitors might vary in patients with different genotype backgrounds. Our data suggest that the higher response rate in the Japanese may be because of reduced *EGFR* expression associated with allele 20 (the most common allele in Asians; Ref. 17).

The most common adverse effect of EGFR inhibitors is cutaneous toxicity, such as skin rash (1). The appearance of skin rash seems to be associated with occurrence of antitumor response but is not clearly related to the dose level administered (26), also supporting the hypothesis that response to EGFR inhibitors has a genetic component. Given the high expression of *EGFR* in the epidermal tissue (27) and the proposed effect of (CA)<sub>n</sub> polymorphism on *EGFR* expression, it is plausible that the (CA)<sub>n</sub> genotype is associated with the sensitivity of both epidermal and tumor tissues to *EGFR* inhibitors, although other genetic determinants such as effectors in the signal transduction cascade may also contribute to this association.

Overexpression of *EGFR* in cancer cells has been significantly shown to be associated with disease stage, prognosis, survival, and response to chemotherapy (2–11), whereas the level of *EGFR* expression is primarily regulated by the abundance of its mRNA (28, 29). Therefore, the (CA)<sub>n</sub> polymorphism may at least partly contribute to the overexpression of *EGFR* (20) and influence the clinical outcome. In a preliminary report of an association study between this polymorphism and clinical response to 5-fluorouracil/oxaliplatin treatment in patients with metastatic colorectal cancer, patients with genotype 16/16 showed poor drug response and overall survival compared with those with 16/18 and 16/20 genotypes (30).

Our study provides an important starting point for better understanding the molecular basis underlying ethnic differences in response to EGFR inhibitors and may be helpful for the future strategies of individualized therapy with molecules targeting EGFR. However, there are some limitations in our study, and several questions still should be addressed. For example, the sample size of Asian samples is relatively small. It should also be emphasized that other polymorphisms in linkage disequilibrium with the (CA)<sub>n</sub> repeat may also contribute to variability in

*EGFR* expression. Therefore, additional studies with large sample size are required to evaluate the haplotype, relationship among genotypes, *EGFR* expression, and clinical outcomes of EGFR-targeting drugs.

## REFERENCES

- Herbst, R. S., and Langer, C. J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. *Semin. Oncol.*, 29(Suppl. 4): 27–36, 2002.
- Lacroix, H., Iglehart, J. D., Skinner, M. A., and Kraus, M. H. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. *Oncogene*, 4: 145–151, 1989.
- Klijn, J. G., Berns, P. M., Schmitz, P. I., and Foekens, J. A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. *Endocr. Rev.*, 13: 3–17, 1992.
- Veale, D., Kerr, N., Gibson, G. J., Kelly, P. J., and Harris, A. L. The relationship of quantitative *epidermal growth factor receptor* expression in non-small cell lung cancer to long term survival. *Br. J. Cancer*, 68: 162–165, 1993.
- Glynne-Jones, E., Goddard, L., and Harper, M. E. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. *Hum. Pathol.*, 27: 688–694, 1996.
- Volm, M., Rittgen, W., and Drings, P. Prognostic value of *ERBB-1*, *VEGF*, *cyclin A*, *FOS*, *JUN* and *MYC* in patients with squamous cell lung carcinomas. *Br. J. Cancer*, 77: 663–669, 1998.
- Fischer-Colbrie, J., Witt, A., Heinzl, H., Speiser, P., Czerwenka, K., Sevela, P., and Zeillinger, R. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. *Anticancer Res.*, 17: 613–619, 1997.
- Niikura, H., Sasano, H., Sato, S., and Yajima, A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. *Int. J. Gynecol. Pathol.*, 16: 60–68, 1997.
- Neskovic-Konstantinovic, Z., Nikolic-Vukosavljevic, D., Brankovic-Magic, M., Kanjer, K., Gavrilovic, D., Mitrovic, L., Borojevic, N., Vukotic, D., and Spuzic, I. Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease. *J. Exp. Clin. Cancer Res.*, 18: 347–355, 1999.
- Ohsaki, Y., Tanno, S., Fujita, Y., Toyoshima, E., Fujiuchi, S., Nishigaki, Y., Ishida, S., Nagase, A., Miyokawa, N., Hirata, S., and Kikuchi, K. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. *Oncol. Rep.*, 7: 603–607, 2000.
- Nicholson, R. I., Gee, J. M., and Harper, M. E. *EGFR* and cancer prognosis. *Eur. J. Cancer* 37(Suppl. 4): S9–S15, 2001.
- Wu, X., Fan, Z., Masui, H., Rosen, N., and Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. *J. Clin. Investig.*, 95: 1897–905, 1995.
- Liu, B., and Fan, Z. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. *Oncogene*, 20: 3726–3734, 2001.
- Ciardello, F., and Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. *Clin. Cancer Res.*, 7: 2958–2970, 2001.
- Chan, K. C., Knox, W. F., Gee, J. M., Morris, J., Nicholson, R. I., Potten, C. S., and Bundred, N. J. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. *Cancer Res.*, 62: 122–128, 2002.
- Ciardello, F., and Tortora, G. Anti-epidermal growth factor receptor drugs in cancer therapy. *Expert Opin. Investig. Drugs*, 11: 755–768, 2002.

17. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., Nishiwaki, Y., Vansteenkiste, J. F., Kudo, S., Averbuch, S., Macleod, A., Feyereislova, A., and Baselga, J. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). *Proc. Am. Soc. Clin. Oncol.*, *21*: 298a, 2002.
18. Chi, D. D., Hing, A. V., Helms, C., Steinbrueck, T., Mishra, S. K., and Donis-Keller, H. Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (*EGFR*) and pro  $\alpha$  2 (I) collagen (*COL1A2*). *Hum. Mol. Genet.*, *1*: 135, 1992.
19. Gebhardt, F., Zanker, K. S., and Brandt, B. Modulation of *epidermal growth factor receptor* gene transcription by a polymorphic dinucleotide repeat in intron 1. *J. Biol. Chem.*, *274*: 13176–13180, 1999.
20. Buerger, H., Gebhardt, F., Schmidt, H., Beckmann, A., Huttmacher, K., Simon, R., Lelle, R., Boecker, W., and Brandt, B. Length and loss of heterozygosity of an intron 1 polymorphic sequence of *EGFR* is related to cytogenetic alterations and epithelial growth factor receptor expression. *Cancer Res.*, *60*: 854–857, 2000.
21. Liu, W., Wang, H., Zhao, S., Zhao, W., Bai, S., Zhao, Y., Xu, S., Wu, C., Huang, W., Chen, Z., Feng, G., and He, L. The novel gene locus for agenesis of permanent teeth (He-Zhao deficiency) maps to chromosome 10q11.2. *J. Dent. Res.*, *80*: 1716–1720, 2001.
22. Evans, W. E., and Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. *Science (Wash. DC)*, *286*: 487–491, 1999.
23. Marsh, S., Collie-Duguid, E. S., Li, T., Liu, X., and McLeod, H. L. Ethnic variation in the *thymidylate synthase* enhancer region polymorphism among Caucasian and Asian populations. *Genomics*, *58*: 310–312, 1999.
24. Marsh, S., Ameyaw, M. M., Githang'a, J., Indalo, A., Ofori-Adjei, D., and McLeod, H. L. Novel *thymidylate synthase* enhancer region alleles in African populations. *Hum. Mutat.*, *16*: 528, 2000.
25. Mcleod, H., and Ameyaw, M. Ethnicity and pharmacogenomics. In: J. Licinio and M-L. Wong (eds.), *Pharmacogenomics: The Search for Individualized Therapies*. Weinheim: Wiley-Vach., 489–514, 2002.
26. Cohen, E., Rosen, F., Dekker, A., Bajda, C., Stenson, K., Shulman, K., Lamont, E., Kozloff, M., and Vokes, E. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). *Proc. Am. Soc. Clin. Oncol.*, *21*: 225a, 2002.
27. Carpenter, G. Receptors for epidermal growth factor and other polypeptide mitogens. *Annu. Rev. Biochem.*, *56*: 881–914, 1987.
28. Merlino, G. T., Ishii, S., Whang-Peng, J., Knutsen, T., Xu, Y. H., Clark, A. J., Stratton, R. H., Wilson, R. K., Ma, D. P., Roe, B. A., et al. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. *Mol. Cell. Biol.*, *5*: 1722–1734, 1985.
29. Merlino, G. T., Xu, Y. H., Richert, N., Clark, A. J., Ishii, S., Banks-Schlegel, S., and Pastan, I. Elevated *epidermal growth factor receptor* gene copy number and expression in a squamous carcinoma cell line. *J. Clin. Investig.*, *75*: 1077–1079, 1985.
30. Zhang, W., Stoehlmacher, J., Park, D. J., Groshen, S., Tsao-Wei, D., Zahedy, S., Lu, B., Gil, J., Mallik, N., and Lenz, H-J. A polymorphic dinucleotide repeat in intron 1 of *EGFR* (*epithelial growth factor receptor*) gene is associated with clinical response to platinum based chemotherapy in patients with advanced colorectal disease. *Proc. Am. Soc. Clin. Oncol.*, *21*: 134a, 2002.

# Clinical Cancer Research

## Interethnic Difference in the Allelic Distribution of Human Epidermal Growth Factor Receptor Intron 1 Polymorphism

Wanqing Liu, Federico Innocenti, Peixian Chen, et al.

*Clin Cancer Res* 2003;9:1009-1012.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/9/3/1009>

**Cited articles** This article cites 26 articles, 6 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/9/3/1009.full#ref-list-1>

**Citing articles** This article has been cited by 25 HighWire-hosted articles. Access the articles at:  
<http://clincancerres.aacrjournals.org/content/9/3/1009.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/9/3/1009>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.